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Abstract Xanthohumol (XN) is the major prenylated flavonoid
of hop plants and has been detected in beer. Previous studies
suggest a variety of potential cancer chemopreventive effects for
XN, but there is no information on its metabolism. The aim of
this study was to investigate in vitro glucuronidation of XN by
rat and human liver microsomes. Using high-performance liquid
chromatography, two major glucuronides of XN were found with
either rat or human liver microsomes. Release of the aglycone by
enzymatic hydrolysis with L-glucuronidase followed by liquid
chromatography/mass spectrometry and nuclear magnetic reso-
nance analysis revealed that these were C-4P and C-4 mono-
glucuronides of XN. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Flavonoids are a group of phenolic compounds that natu-
rally occur in fruits, vegetables, nuts, seeds, £owers, and bark.
More than 4000 di¡erent £avonoids have been described.
They have been considered inert and non-essential for human
health; however, in the last few years it has been shown that
£avonoids a¡ect a wide variety of biological systems in mam-
mals, exhibiting antioxidant, anti-in£ammatory, antiviral,
antiproliferative, and anticarcinogenic e¡ects [1]. Studies
show that several £avonoids can inhibit or activate the cyto-
chrome P450 (CYP) enzyme system in vitro and in vivo [2,3].
Recently in animal studies much attention has been paid to
the antioxidant properties and the inhibitory role of £avo-
noids in various stages of tumor development. This improved
understanding of the biological and pharmacological proper-
ties of individual £avonoid compounds has led to the develop-
ment of £avonoid drugs which contain either naturally occur-
ring £avonoids or their chemically modi¢ed derivatives [4].
Hop (Humulus lupulus L.) cones are known not only as
brewing materials but also in Europe as a medicinal plant.
Even today, hop is used as a tranquilizer in folk medicine
[5]. Xanthohumol (XN), which has a prenylated chalcone
structure (Fig. 1B), is the principal £avonoid present in hop
£ower (cone) extracts [6] and is present in beer [7]. Studies
have shown that XN is an e¡ective antiproliferative agent in
human breast cancer cells (MCF-7), colon cancer cells (HT-
29) and ovarian cancer cells (A-2780) [8]. It also was shown
that XN inhibited bone resorption and has been patented as a
drug for osteoporosis treatment [9].
Although £avonoids are abundant, little is known about
their fate in animals. Flavonoid biotransformation is primar-
ily catalyzed by the liver and the gut micro£ora [10]. In a
recent study, we showed that XN was metabolized to four
di¡erent metabolites by isosafrole/L-naphtho£avone (ISF/
BNF) -induced rat liver microsomes [11]. Numerous studies
have been published demonstrating that many types of £avo-
noids are excreted as glucuronides by humans or other mam-
mals [12,4]. Glucuronidation is the main pathway of the Phase
II detoxi¢cation processes for most xenobiotics, including £a-
vonoids, and is catalyzed by UDP-glucuronosyl transferases
which are membrane-bound and located mainly in the liver
endoplasmic reticulum [13]. It is also known that £avonoids
may be conjugated in vivo yielding metabolites that exhibit
antioxidant properties [1].
The glucuronidation of £avonoids such as diosmetin, quer-
cetin, genistein, rutin, and kaempferol has been investigated in
rat and human, but there is no information about glucuroni-
dation of prenylated £avonoids. This study is the ¢rst one to
demonstrate that XN, a prenylated £avonoid, produced glu-
curonides by liver microsomes from human or rats untreated
or rats pretreated with various CYP-inducing agents, includ-
ing phenobarbital (PB), ISF, and BNF. The glucuronides were
characterized by high-performance liquid chromatography
(HPLC), UV spectroscopy, liquid chromatography/mass spec-
trometry (LC/MS), and proton nuclear magnetic resonance
(1H-NMR).
2. Materials and methods
2.1. Chemicals
XN was isolated and puri¢ed from hop as described [6]. Formic
acid, L-glucuronidase (Type B-1: from bovine liver), PB, BNF and
uridine 5P-diphosphoglucuronic acid (UDPGA) were purchased from
Sigma Chemical Company (St. Louis, MO, USA). ISF was from
Aldrich Co. (Milwaukee, WI, USA). Acetonitrile, ethanol and meth-
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anol were HPLC grade from Mallinckrodt Baker, Inc. (Paris, KY,
USA). Dimethyl-d6 sulfoxide (100%) and MgCl2 were purchased from
Cambridge Isotope Laboratories, Inc. (Andover, MA, USA) and Ko-
dak (Rochester, NY, USA), respectively. Human liver microsomes
were purchased from Genetest.
2.2. Isolation of rat liver microsomes
Sixteen male Sprague^Dawley rats (165^185 g body weight) were
purchased from Simonsen Company (Gilroy, CA, USA). Animals
were divided into four groups with four animals in each cage. Micro-
somes were prepared as described [14] from pooled livers or rats that
had been treated intraperitoneally with 0.9% NaCl, PB (80 mg/kg) in
NaCl, ISF (150 mg/kg) in corn oil, or BNF (40 mg/kg) in corn oil
daily for 3 days. On the fourth day after exposure, preceded by a 24-h
fasting period, the rats were anaesthetized using CO2 and killed by
asphyxiation. The washed liver microsomes, resuspended in 0.1 M
potassium phosphate bu¡er, pH 7.4, containing 20% glycerol and
1 mM EDTA, were frozen at 380‡C before use. Protein concentra-
tions of liver microsomes were determined by Coomassie Plus1 Pro-
tein Assay from Pierce Chemical Co. (Rockford, IL, USA). P450
contents were determined by the method of Omura and Sato [15].
2.3. XN glucuronidation by rat or human liver microsomes
A typical 0.5-ml incubation mixture consisted of 0.5 mg protein of
microsomes from untreated or PB-, ISF-, or BNF-treated rats or
human liver microsomes, 52 mM HEPES/NaOH bu¡er pH 7.4 con-
taining 10 mM MgCl2, 0.25 mM Triton X-100, 52 mM UDPGA, and
100 WM XN (dissolved in 3 Wl ethanol) as a substrate [12]. The re-
action was initiated by adding UDPGA. Incubations were carried out
at 37‡C for 60 min with continuous shaking in a Dubno¡ incubator.
Control incubations were performed without the addition of UDPGA
or without microsomes. Reactions were terminated by adding 1.5 ml
ice-cold methanol, followed by centrifugation at 4‡C. The superna-
tants were evaporated to dryness under nitrogen gas. The residues
were redissolved in 100 Wl 25% CH3CN containing 1% formic acid,
and subsequently analyzed on the same day by HPLC for XN metab-
olites. All experiments were carried out in duplicate. Sets of experi-
ments also were done with ethanol alone or without microsomes.
2.4. Time course of glucuronidation of XN
Liver microsomes from untreated rats were used in incubations as
described above with a ¢nal volume of 250 Wl. Reactions were stopped
at 0, 10, 20, 30, 40, 50, and 60 min by adding ice-cold MeOH. The
procedure described above was followed to analyze in HPLC.
2.5. Hydrolysis with L-glucuronidase
The dried fractions or incubation samples were incubated in 50 mM
phosphate bu¡er (pH 5.5) with the presence of 1000 units/ml of L-
glucuronidase for 1.5 h at 37‡C with a ¢nal volume of 250 Wl. Con-
trols were run simultaneously under the same conditions without L-
glucuronidase. All reactions were carried out in duplicate. The reac-
tions were stopped by adding 500 Wl of ice-cold MeOH and centri-
fuged for 20 min. The supernatant was analyzed by HPLC.
2.6. HPLC and isolation of metabolites by HPLC
A waters 2690 HPLC system with a 996 diode-array detector and a
4 Wm Nova-Pak C18 column (3.9U150 mm, Waters) were used to
separate metabolites. Detection was at 370 nm. Samples dissolved in
100 Wl 75% aqueous acetonitrile containing 1% formic acid were an-
alyzed using a slight modi¢cation of the method of Nielsen et al. [2].
Metabolites were eluted with acetonitrile and water containing 1%
formic acid at a £ow rate of 0.8 ml/min. The initial 29% CH3CN
was increased to 60% over 18 min and then to 84% over the next
10 min with a linear gradient function. At 34 min, the CH3CN was
returned to 29% in 4 min. The metabolites were identi¢ed by LC/MS
and 1H-NMR after running a large-scale incubation with 1.27 mg XN
and collecting fractions of this incubation by preparative HPLC with
an Alltech Econosil C18 (250U22 mm) column at a £ow rate of 11 ml/
min. All isolated metabolite fractions were lyophilized and redissolved
in 25% CH3CN containing 1% formic acid before LC/MS analysis.
2.7. LC/MS
LC/MS was performed with Waters 6000A pumps using a 5 Wm C18
column (250U4.0 mm) at a £ow rate of 0.8 ml/min. XN metabolites
were separated with a linear solvent gradient starting from 40%
CH3CN to 100% CH3CN in 1% aqueous formic acid over 30 min.
At 35 min, the percentage CH3CN was returned to 40% in 2 min, and
the column was equilibrated for 15 min prior to the next injection.
Mass spectra were recorded on a PE Sciex API III+ triple quadrupole
mass spectrometer using atmospheric-pressure chemical ionization in
positive mode, with an ori¢ce voltage of +55 V, source temperature of
60‡C, and scanning from m/z 110 to 800. Samples were introduced by
loop injection or by HPLC via the heated nebulizer interface set at
500‡C. After data acquisition, multiple-ion monitoring was employed
for selective detection of metabolites. Daughter-ion scanning in the
MS^MS mode was used to obtain structural information. The target
gas in the collision cell was argon:nitrogen (9:1) at a density of ca
1.8U1014 atoms cm32. The collision energy was set at 15 V.
2.8. NMR
1H-NMR spectra of metabolite glucuronide 1 (G1) and G2 frac-
tions were recorded in DMSO-d6 at room temperature on a Bruker
DRX 600 spectrometer at 600 and 150.9 MHz. DMSO resonances at
2.5 and 39.51 ppm were used as internal shift references. 1H^H COSY
was performed using standard pulse sequences.
3. Results and discussion
XN is the major prenylated chalcone in hop and beer. It is
of general interest to humans because it represents a dietary
£avonoid with signi¢cant biological activities [8]. In previous
work, the oxidative metabolism of XN was studied using rat
liver microsomes [11]. The present study deals with glucuro-
nidation of XN investigated by incubation of XN with UDP-
GA and liver microsomes from rats or humans. The glucur-
onides were characterized by HPLC, LC/MS and NMR
analysis. Untreated male rat liver microsomes metabolized
XN to two major and two minor glucuronides, designated
G1, G2, G3, G4 (Fig. 1). The retention times for XN and
its glucuronides were as follows; XN -17.6 min; G1 -9.6
min; G2 -11.2 min; G3 -3.4 min; and G4 -5.0 min. Liver
Fig. 1. A typical HPLC chromatogram of XN glucuronidation
mediated by liver microsomes from untreated rats with UDPGA
(A) and without UDPGA (B).
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microsomes from rats pretreated with PB (an inducer of
CYP2B1 and CYP2B2), ISF (a CYP1A inducer) or BNF (a
CYP1A inducer) [16], yielded the same four glucuronides. The
relative proportions of these glucuronides was not a¡ected by
the di¡erent CYP inducers which is in agreement with pre-
vious studies and which shows that the microsomal UGTs
responsible for the conjugation of £avonoids are not inducible
by CYP1A and CYP2B inducers [12]. Based on integrated
peak areas, G1 and G2 represented approximately 89% and
10% of total glucuronides formed in incubations, respectively.
G3 or G4, however, only accounted for about 1% of total
glucuronides. Human liver microsomes (H056) that were
rich in CYP1A2 formed only the G1 and G2 glucuronides.
However, human liver microsomes (H112) that were rich in
CYP3A4 produced a small amount of the third glucuronide,
G3, in addition to G1 and G2. This may be a result of di¡er-
ent concentrations of UDP-glucuronosyl transferase isozymes
in the two human liver microsomal samples. Control incuba-
tions were carried out without UDPGA or microsomes. No
glucuronidation of XN occurred in the absence of UDPGA,
and neither were glucuronides formed when liver microsomes
(rat or human) were absent (Fig. 1B).
L-Glucuronidase treatment of the mixture of four glucuro-
nides caused a substantial decrease of amounts of G1, G2, G3
and G4 (95, 91, 96, and 92%, respectively) and a 30% increase
of XN. The hydrolytic cleavage experiments with bovine liver
L-glucuronidase con¢rms that metabolites G1 through G4, are
glucuronide conjugates. The time course of glucuronidation of
XN by untreated male rat liver microsomes showed an in-
crease of glucuronide formation and a corresponding decrease
of parent compound, XN, over a 1.0-h incubation period.
The treatment of the G1 and G2, obtained by preparative
HPLC, with L-glucuronidase led to the disappearance of G1
and G2 and the concomitant appearance of XN (Figs. 2 and
3, respectively).
The structures of two major glucuronides, G1 and G2, were
identi¢ed as monoglucuronides of XN by UV, LC/MS and 1H
NMR analysis after preparative HPLC isolation of the glu-
curonides. G1 showed a maximum UV absorption at 370 nm
similar to the chalcone £avonoid XN. In LC/MS studies the
molecular weight, 530 Da, of G1 suggested that the conjugate
contained a glucuronide group attached to XN (Fig. 4A).
Upon MS^MS fragmentation of the MH ion, loss of the
prenyl moiety from glucuronide, and loss of glucuronide
from the parent compound, were most prominent, giving
rise to fragments with m/z 475 [531^56], and 355 [531^
176], respectively. The intensity of the fragment with m/z
355 was greater than that of m/z 475 indicating that CQ^C2Q
cleavage of the prenyl group was more di⁄cult in G1 than in
G2 (compare Fig. 4A and B). This suggested that in G1 the
glucuronide residue was attached to OH-4P because cleavage
of the 1Q^2Q bond of the prenyl substituent leaves an Ar-CH2
fragment ion which is stabilized by a free ortho hydroxyl
group [6]. Apparently, such a free hydroxyl group was not
available in G1, rendering loss of the prenyl substituent less
favorable. In G1, the hydroxyl group at C-4P was connected
to the glucuronide residue while OH-2P was chelated with the
keto function of XN. Further fragments of G1 were observed
at m/z 299 [355^56] and 179 [A-C4H8]. Proton NMR anal-
ysis of G1 showed an OMe resonance at N 3.91 (singlet) and
two ole¢nic protons, H-K and H-L (broad singlet at N 7.71,
integrating for two protons). The B-ring protons, H-2/H-6
and H-3/H-5, appeared as a set of doublets at N 7.59 and
6.85 (J = 10 Hz). The aromatic ring proton H-5P gave a singlet
at N 6.47. Other signals were attributed to 2P-OH (N 14.61), H-
2Q (N 4.99), and H-1Q (N 3.17). Compared to XN (NH50 6.0) and
Fig. 2. HPLC chromatogram of G1 before (A) and after (B) L-glu-
curonidase treatment.
Fig. 3. HPLC chromatogram of G2 before (A) and after (B) L-glu-
curonidase treatment.
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G2 (NH50 6.14), the H-5P resonance of G1 (NH50 6.47) resonated
at lower ¢eld. This strongly suggested that the glucuronide
residue was connected ortho to C-5P, that is, to the oxygen
atom at C-4P.
G2 was formed at lower concentrations than G1 by both
rat or human liver microsomes. The UV spectrum of G2
showed maximum absorption at 359 nm similar to the chal-
cone £avonoid XN. Its molecular weight, 530 Da, suggested
that G2 contained a glucuronide group attached to XN (Fig.
4B). MS^MS fragmentation of the MH ion yielded the same
fragments as G1. The most conspicuous di¡erence between
the fragmentation patterns of G1 and G2 was the relative
intensity of the fragment ions. In G2, loss of the prenyl sub-
stituent was more favorable than cleavage of the glucuronic
acid residue judging from the greater intensity of the [531^
56] ion. This suggested that the glucuronic acid molecule was
connected to the B-ring hydroxyl at C-4 in G2, leaving the
OH-4P available for stabilization of the Ar-CH2 fragment
with m/z 475. Proton NMR analysis of G1 showed an OMe
resonance at N 3.85 (singlet) and two ole¢nic protons, H-K
and H-L (broad singlet at N 7.84, integrating for two protons).
The B-ring protons, H-2/H-6 and H-3/H-5, appeared as a set
of doublets at N 7.66 and 7.08 (J = 10 Hz). The aromatic ring
proton H-5P gave a singlet at 6.14. Other signals were at
N 14.60 (2P-OH) and N 4.98 (H-2Q). The observation that the
B-ring protons resonated at 0.1^0.2 ppm lower ¢eld in G2
than in G1 suggested the position of the glucuronide residue
at OH-4 in G2. The formation of O-glucuronides was ex-
pected as shown in other studies of £avonoids [17,18].
G3 and G4 produced UV maxima at 262/362 nm and 262/
358 nm, respectively. In LC/MS studies both conjugates gave
pseudo-molecular ions with m/z 531, con¢rming that both
minor metabolites were monoglucuronides. L-Glucuronidase-
catalyzed hydrolysis of G3, obtained by preparative HPLC,
gave rise to a mixture of XN and its £avanone isomer, iso-
xanthohumol (IX). These data suggest that G3 may be a
glucuronide of IX with the glucuronide portion attached to
either one of the two free hydroxyls, OH-4 or OH-4P (in the
£avanone, IX, OH-2P is ¢xed in a Q-pyranone system). Since
IX can be formed from XN by non-enzymatic isomerization,
it is possible that the IX formed by hydrolysis of its glucur-
onide conjugate could reisomerize to form XN. Alternatively,
the IX glucuronide could co-chromatograph with a glucuro-
nide of XN (possibly the 2P-OH glucuronide) so that both IX
and XN are released upon L-glucuronidase hydrolysis. Anoth-
er possibility is that G3 is a di¡erent positional glucuronide
isomer of IX.
G4 was obtained in insu⁄cient amounts for further char-
acterization. However, since the UV and MS^MS data
showed that it was monoglucuronide, there was a possibility
that G4 was a monoglucuronide of a XN metabolite formed
non-enzymatically in these incubation conditions. For exam-
ple, the involvement of the non-enzymatic oxidations in XN
metabolite formation, such as M1, has been shown [11].
Glucuronidation of XN at position C4P (G1) appears to be
favored above glucuronidation at C4 (G2) in these experi-
ments. This suggests that the presence of a prenyl group in
the A ring does not preclude glucuronyl transferase-catalyzed
O-glucuronidation of XN as expected due to limited accept-
ability of the substrate as a results of steric hindrance.
In this study, we have shown that rat and human liver
microsomes readily convert XN to glucuronides. Flavonoids
are also conjugated in vivo, yielding £avonoid glucuronides
that exhibit a variety of biological activities, such as antioxi-
dant [1] and estrogenic activities, and activation of human
natural killer cells [19]. Most previous research has not been
conducted with non-prenylated £avonoids. It is not yet known
if dietary prenylated £avonoids (0.4^4.0 mg/l in hopped beers)
are conjugated in vivo and whether or not the resulting glu-
curonides have biological activity.
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